Skip to main content
. 2022 Mar 15;43(10):2636–2650. doi: 10.1038/s41401-022-00889-4

Fig. 4. Sotagliflozin enhances skeletal muscle cells angiogenesis potentials through HIF-1α under hyperglycemia.

Fig. 4

a, b Protein expression levels of angiogenic factors in C2C12 cells treated with 10 μM sotagliflozin and 2-ME2 under hyperglycemia, as examined using Western blotting. Representative images (a) and quantification results (b) were shown. c, d Proliferation potential of C2C12 cells treated with 10 μM sotagliflozin and 2-ME2 under hyperglycemia, as evaluated by EdU incorporation assay. Representative images (c; scale bars: 100 μm) and quantification results (d; n = 6) were shown. e, f Migration potential of C2C12 cells treated with 10 μM sotagliflozin and 2-ME2 under hyperglycemia, as investigated using transwell migration assay. Representative images (e; scale bars: 200 μm) and quantification results (f; n = 6) were shown. Cells treated with 10% DMSO under hyperglycemia were used as controls. β-Actin was used as Western blotting loading control. Data were presented as mean ± SD (n = 3, unless further indicated). **P < 0.01; ***P < 0.001.